论文部分内容阅读
依西美坦(exemestane)是在英国批准上市的一种选择性芳香酶抑制剂,在欧洲注册前美国已用于绝经后妇女晚期乳腺癌的治疗。芳香酶抑制剂通过选择性抑制雌激素的生物合成是绝经后妇女乳腺癌激素治疗的一个重要手段。因为绝经后妇女雌激素来源的主要生物合成途径是通过芳香酶催化外
Exemestane is a selective aromatase inhibitor approved for marketing in the United Kingdom and has been used in the United States for the treatment of advanced breast cancer in postmenopausal women in Europe. Aromatase inhibitors are an important means of hormonal treatment of breast cancer in postmenopausal women by selectively inhibiting estrogen biosynthesis. Because the main biosynthetic pathway of estrogen in postmenopausal women is catalyzed by aromatase